Medicenna Therapeutics
Company Overview
Company Type: Public Company
Website: www.medicenna.com
Number of Employees: 16
Ticker: MDNA (TSX)
Year Founded: 2017


Business Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
27.5
EBITDA
(16.4)
Total Enterprise Value
(2.1)
TEV/EBITDA
NM
EBIT
(16.4)
Cash & ST Invst.
29.6
P/Diluted EPS Before Extra
NM
Net Income
(8.8)
Total Debt
0.0
Price/Tang BV
1.0x
Total Assets
31.5


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Mar-31-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.07)
(0.07)
(0.24)
(0.29)
(0.28)
Revenue (mm)
0.00
0.00
0.60
0.60
0.60

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
NM
P/BV
2.08x

Non-Periodic Estimates

Recommendation
Buy (1.20)
Target Price
5.00
Potential Upside
1,233.33%


Key Professionals
Name
Title
Merchant, Fahar 
Founder, Chairman, President & CEO
Merchant, Rosemina 
Founder & Chief Development Officer
Caravella, Jeff 
Chief Financial Officer
Bexon, Martin 
Acting Chief Medical Officer & Head of Clinical Development
Meadows, Brent 
Chief Business Officer
Denmeade, Samuel R.
Scientific Advisor

Key Board Members
Name
Title
Merchant, Fahar 
Founder, Chairman, President & CEO
Beraldo, Albert George
Lead Independent Director
Dawes, Karen A.
Independent Director
Geltosky, John 
Independent Director
Quezada, Sergio A.
Chairman of Scientific Advisory Board
Ascierto, Paolo Antonio
Member of Clinical Advisory Board
Becher, Burkhard 
Member of Scientific Advisory Board
Dhingra, Kapil 
Strategic Advisor
Mooney, David J.
Member of Scientific Advisory Board
Redmond, William L.
Member of Scientific Advisory Board
Sampson, John H.
Independent Director
Siu, Lillian L.
Member of Clinical Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
2 Bloor Street West 7th Floor | Toronto, ON | M4W 3E2 | Canada
Phone: 416- 648-5555   

Current and Pending Investors
Esperante Ventures

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.38
Market Cap (mm)
26.1
Open
 0.38
Shares Out. (mm)
69.6
Previous Close
 0.38
Float %
70.0%
Change on Day
(0.02)
Shares Sold Short (mm)
-
Change % on Day
(5.1)%
Dividend Yield %
-
Day High/Low
 0.38/ 0.38
Diluted EPS Excl. Extra Items
(0.13)
52 wk High/Low
 1.21/ 0.36
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0011
Avg 3M Dly Vlm (mm)
0.05
Beta 5Y
0.77


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
TSX:MDNA - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
A2 Acquisition Corp.
As of March 1, 2017, A2 Acquisition Corp. was acquired by Medicenna Therapeutics, Inc., in a reverse merger transaction. A2 Acquisition Corp. does not have significant operations. It intends to identify and evaluate potential acquisitions or businesses with a view to complete a qualifying transaction. The company was incorporated in 2015 and is headquartered in Calgary, Canada.

United States and Canada
Asset Management and Custody Banks
-
1.00
0.00
Greenhawk Resources Inc. (CNSX:GRHK)
Greenhawk Resources Inc. operates as a mineral exploration company in Greenland. It holds 100% owned interests in two mineral exploration licenses and one prospecting license in the Storo Gold Project. The company was formerly known as Cryptologic Corp. and changed its name to Greenhawk Resources Inc. in May 2021. Greenhawk Resources Inc. is headquartered in Toronto, Canada.

United States and Canada
Diversified Metals and Mining
-
3.00
0.00
Medicenna Biopharma Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-17-2023
-
Shelf Registration
Target
Medicenna Therapeutics Corp. (TSX:MDNA)


100.00
Feb-17-2023
-
Public Offering
Target
Medicenna Therapeutics Corp. (TSX:MDNA)


10.00
Aug-8-2022
Aug-9-2022
Public Offering
Target
Medicenna Therapeutics Corp. (TSX:MDNA)


20.00
Dec-30-2020
-
Public Offering
Target
Medicenna Therapeutics Corp. (TSX:MDNA)


25.00
Jul-31-2020
-
Shelf Registration
Target
Medicenna Therapeutics Corp. (TSX:MDNA)


27.09
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-03-2023
Product-Related Announcements
Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
Oct-02-2023
Company Conference Presentations
Medicenna Therapeutics Corp. Presents at The AACR Special Conference on Tumor Immunology and Immunotherapy, Oct-02-2023 04:45 PM
Sep-28-2023
Executive/Board Changes - Other
Medicenna Therapeutics Corp. Announces Board Resignations
Sep-28-2023
Changes in Company Bylaws/Rules
Medicenna Therapeutics Corp. Approves Adoption of an Amendment to the Company's Articles
Sep-28-2023
Shareholder/Analyst Calls
Medicenna Therapeutics Corp. - Shareholder/Analyst Call


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
Private Placement Advisors
Bloom Burton & Co. Inc., Gowling WLG International Limited, Haywood Securities (USA) Inc., Research Capital USA Inc., Richardson GMP Limited, Investment Banking Arm
Public Offering Advisors
Baker McKenzie LLP (Canada), Davidson & Company LLP, Maxim Group LLC, McCarthy TÃ©trault LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Troutman Pepper Hamilton Sanders LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

04:05 AM
MDNA
Medicenna Therapeutics Corp 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:24 AM
MDNA
ValuEngine - Toronto Quantitative Stock Report for MDNA
Reports
5
ValuEngine, Inc.

Oct 02, 2023 04:56 AM
MDNA
ValuEngine Rating and Forecast Report for MDNA
Reports
11
GlobalData

Sep 15, 2023 03:10 AM
MDNA
Medicenna Therapeutics Corp (MDNA.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
137
MarketLine

Sep 14, 2023 06:01 AM
MDNA
Medicenna Therapeutics Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
189
GlobalData

Sep 13, 2023 02:19 AM
MDNA
Medicenna Therapeutics Corp (MDNA.TSE) - Financial Analysis Review
Reports
310
S&P Global Compustat

Sep 07, 2023 04:08 AM
MDNA
Medicenna Therapeutics Corp 2023_09_07
Reports
14
GlobalData

Aug 25, 2023 03:27 AM
MDNA
Medicenna Therapeutics Corp (MDNA.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
57
Zacks Small-Cap Research
Bautz, David
Aug 15, 2023 02:02 PM
MDNA
MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial
Reports
6
Oppenheimer & Co. Inc.
Biegler, Matthew Cornell
Aug 14, 2023 09:51 AM
MDNA
Dose Escalation Update Identifies Sweet Spot Expansion Dose
Notes
7


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Aries Biologics Inc

5,500,000

7.90

2.1

Aug-09-2023


Merchant Ph.D., Fahar 

5,351,400

7.68

2.1

Sep-28-2023


Merchant B.Sc., M.E.Sc, Rosemina 

5,250,000

7.54

2.1

Sep-28-2023


Aigh Capital Management, LLC

4,339,983

6.23

1.7

Jun-30-2023


AWM Investment Company Inc

1,000,000

1.44

0.4

Jun-30-2023


Hudson Bay Capital Management LP

780,564

1.12

0.3

Jun-30-2023


Dafna Capital Management, LLC

660,000

0.95

0.3

Jun-30-2023


Verition Fund Management LLC

589,500

0.85

0.2

Jun-30-2023


Beraldo C.A., C.P.A., CPA, Albert George

325,000

0.47

0.1

Sep-28-2023


Sigma Planning Corporation

305,300

0.44

0.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Susquehanna International Group, LLP, Asset Management Arm
53,732
53,732
Virtu Financial LLC, Asset Management Arm
21,530
21,530
Next Edge Capital Corp.
120,000
20,000
Sigma Planning Corporation
305,300
3,250
Two Sigma Securities, LLC, Asset Management Arm
16,386
1,895

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Millennium Management LLC
0
(68,215)
Renaissance Technologies LLC
90,400
(59,900)
Letko, Brosseau & Associates Inc.
120,000
(50,000)
Purpose Investments Inc.
20,130
(47,454)
Hudson Bay Capital Management LP
780,564
(43,483)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-07
Medicenna to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
BiSKITs (Future), MDNA109 (Future), MDNA11 (Future), MDNA11 + KEYTRUDA (Future), MDNA132 (Future), MDNA19 (Future), MDNA209 (Future), MDNA213 (Future), MDNA413 (Future), MDNA55 (Future), MDNA56 (Future), MDNA57 (Future)


Upcoming Events
Date/Time
Type
Oct-09-2023
Company Conference Presentations
Oct-09-2023
Conferences
Oct-19-2023
Company Conference Presentations
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
Oct-03-2023
Medicenna Therapeutics Corp. (TSX:MDNA)
SEC
6-K
23 KB
Oct-03-2023
-
Medicenna Therapeutics Corp. (TSX:MDNA)
SEDAR
News Releases
29 KB
Sep-28-2023
-
Medicenna Therapeutics Corp. (TSX:MDNA)
SEDAR
News Releases
29 KB
Sep-28-2023
Sep-28-2023
Medicenna Therapeutics Corp. (TSX:MDNA)
SEC
6-K
22 KB
Sep-28-2023
Sep-28-2023
Medicenna Therapeutics Corp. (TSX:MDNA)
SEC
6-K
9 KB
Sep-28-2023
-
Medicenna Therapeutics Corp. (TSX:MDNA)
SEDAR
News Releases
68 KB
Sep-06-2023
-
Medicenna Therapeutics Corp. (TSX:MDNA)
SEDAR
News Releases
12 KB
Sep-06-2023
Sep-06-2023
Medicenna Therapeutics Corp. (TSX:MDNA)
SEC
6-K
8 KB
Aug-29-2023
-
Medicenna Therapeutics Corp. (TSX:MDNA)
SEDAR
Management Proxy Materials
222 KB
Aug-29-2023
-
Medicenna Therapeutics Corp. (TSX:MDNA)
SEDAR
Management Proxy Materials
454 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Merchant Ph.D., Fahar  (Founder, Chairman, President & CEO)
Feb-21-2023
Common Shares
30,000
28,078
Open Market Acquisition
0.56
Multiple
Beraldo C.A., C.P.A., CPA, Albert George (Lead Independent Director)
Oct-06-2022 - Oct-11-2022
Common Shares
35,300
41,254
Open Market Acquisition
12.19
Multiple
-
Oct-06-2022
Common Shares
5,600
6,447
Open Market Acquisition
-
Exchange Announcement
-
Oct-07-2022
Common Shares
4,700
5,426
Open Market Acquisition
-
Exchange Announcement
-
Oct-11-2022
Common Shares
25,000
29,381
Open Market Acquisition
-
Exchange Announcement
Beraldo C.A., C.P.A., CPA, Albert George (Lead Independent Director)
Oct-04-2022 - Oct-05-2022
Common Shares
64,700
74,551
Open Market Acquisition
28.76
Multiple
-
Oct-04-2022
Common Shares
46,900
53,985
Open Market Acquisition
-
Exchange Announcement
-
Oct-05-2022
Common Shares
17,800
20,567
Open Market Acquisition
-
Exchange Announcement
Panchal M.Sc., Ph.D., Chandrakant J. (Former Independent Director)
Sep-29-2022
Common Shares
1,000
1,085
Open Market Acquisition
50.00
Multiple
Williams CA, CPA, Elizabeth  (Former CFO & Corporate Secretary)
Mar-09-2022
Common Shares
5,000
9,648
Open Market Acquisition
48.54
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Merchant, Fahar 
Founder, Chairman, President & CEO
604-671-6673
-
fmerchant@medicenna.com
Beraldo, Albert George
Lead Independent Director
416- 648-5555
-

Dawes, Karen A.
Independent Director
416- 648-5555
-

Geltosky, John 
Independent Director
416- 648-5555
-
jgeltosky@azte.com
Quezada, Sergio A.
Chairman of Scientific Advisory Board
416- 648-5555
-

Ascierto, Paolo Antonio
Member of Clinical Advisory Board
416- 648-5555
-

Becher, Burkhard 
Member of Scientific Advisory Board
416- 648-5555
-

Dhingra, Kapil 
Strategic Advisor
1 973 729 3560
-
kd1234@embarqmail.com
Mooney, David J.
Member of Scientific Advisory Board
416- 648-5555
-

Redmond, William L.
Member of Scientific Advisory Board
416- 648-5555
-

Sampson, John H.
Independent Director
416- 648-5555
-

Siu, Lillian L.
Member of Clinical Advisory Board
416- 648-5555
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Merchant, Fahar 
Founder, Chairman, President & CEO
604-671-6673
-
fmerchant@medicenna.com
Merchant, Rosemina 
Founder & Chief Development Officer
416- 648-5555
-

Caravella, Jeff 
Chief Financial Officer
416- 648-5555
-

Bexon, Martin 
Acting Chief Medical Officer & Head of Clinical Development
416- 648-5555
-

Meadows, Brent 
Chief Business Officer
416- 648-5555
-

Denmeade, Samuel R.
Scientific Advisor
416- 648-5555
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâS FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâs opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
